Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.

van der Heijden, Michiel S; Powles, Thomas; Petrylak, Daniel; de Wit, Ronald; Necchi, Andrea; Sternberg, Cora N; Matsubara, Nobuaki; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A; Bamias, Aristotelis; Gakis, Georgios; Lee, Jae-Lyun; Tagawa, Scott T; Vaishampayan, Ulka; Aragon-Ching, Jeanny B; Eigl, Bernie J; Hozak, Rebecca R; Rasmussen, Erik R; Xia, Meng Summer; Rhodes, Ryan; Wijayawardana, Sameera; Bell-McGuinn, Katherine M; Aggarwal, Amit; Drakaki, Alexandra

van der Heijden, Michiel S; Powles, Thomas; Petrylak, Daniel; de Wit, Ronald; Necchi, Andrea; Sternberg, Cora N; Matsubara, Nobuaki; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A; Bamias, Aristotelis; Gakis, Georgios; Lee, Jae-Lyun; Tagawa, Scott T; Vaishampayan, Ulka; Aragon-Ching, Jeanny B; Eigl, Bernie J; Hozak, Rebecca R; Rasmussen, Erik R; Xia, Meng Summer; Rhodes, Ryan; Wijayawardana, Sameera; Bell-McGuinn, Katherine M; Aggarwal, Amit; Drakaki, Alexandra.

Affiliation

van der Heijden MS; The Netherlands Cancer Institute, Amsterdam, The Netherlands. ms.vd.heijden@nki.nl.
Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Petrylak D; Smilow Cancer Hospital at Yale New Haven, Yale New Haven Hospital, New Haven, CT, USA.
de Wit R; Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Necchi A; Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy.
Sternberg CN; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, New York, NY, USA.
Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
Nishiyama H; University of Tsukuba, Tsukuba, Ibaraki, Japan.
Castellano D; Hospital Universitario 12 de Octubre, Madrid, Spain.
Hussain SA; University of Sheffield, Department of Oncology and Metabolism, Sheffield, UK.
Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
Gakis G; University Hospital of Würzburg, Würzburg, Germany.
Lee JL; Asan Medical Center, Urologic Cancer Center, Seoul, South Korea.
Tagawa ST; Weill Cornell Medical College, Department of Genitourinary Oncology, New York, NY, USA.
Vaishampayan U; University of Michigan Ann Arbor, Ann Arbor, MI, USA.
Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, VA, USA.
Eigl BJ; BC Cancer, Vancouver, BC, Canada.
Hozak RR; Eli Lilly and Company, Indianapolis, IN, USA.
Rasmussen ER; Eli Lilly and Company, New York, NY, USA.
Xia MS; Eli Lilly and Company, Indianapolis, IN, USA.
Rhodes R; Eli Lilly and Company, Indianapolis, IN, USA.
Wijayawardana S; Eli Lilly and Company, Indianapolis, IN, USA.
Bell-McGuinn KM; Eli Lilly and Company, Indianapolis, IN, USA.
Aggarwal A; Eli Lilly and Company, Indianapolis, IN, USA.
Drakaki A; David Geffen School of Medicine, Division of Hematology and Oncology, UCLA, Los Angeles, CA, USA.

Nat Commun ; 13(1): 1878, 2022 04 06.

Article de En | MEDLINE | ID: mdl-35388003

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la vessie urinaire / Carcinome transitionnel Type d'étude: Prognostic_studies / Risk_factors_studies Limites: Humans Langue: En Journal: Nat Commun Sujet du journal: BIOLOGIA / CIENCIA Année: 2022 Type de document: Article Pays d'affiliation: Pays-Bas

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google